1. Articles in category: Conferences

    1-24 of 43 1 2 »
    1. When LMO1 Meets MYCN, Neuroblastoma Is Metastatic.

      When LMO1 Meets MYCN, Neuroblastoma Is Metastatic.

      Cancer Cell. 2017 Sep 11;32(3):273-275

      Authors: Liu Z, Thiele CJ

      Abstract LMO1 is a high-risk neuroblastoma susceptibility gene, but how LMO1 cooperates with MYCN in neuroblastoma tumorigenesis is unclear. In this issue of Cancer Cell, Zhu et al. develop a novel zebrafish model that elucidates a mechanism by which LMO1 and MYCN synergistically initiate neuroblastoma and contribute to metastatic disease progression.

      Read Full Article
      Mentions: MYCN Tumorigenesis
    2. Study finds more childhood cancer survivors would likely benefit from genetic screening

      Study finds more childhood cancer survivors would likely benefit from genetic screening

      WASHINGTON, April 3, 2017 /PRNewswire/ -- Twelve percent of childhood cancer survivors carry germline mutations that put them or their children at increased risk of developing cancer, according to a landmark study presented today at the annual meeting of the American Association for...

      Read Full Article
    3. Pregnancy in survivors of childhood cancer may confer elevated risk for cardiotoxicity

      Pregnancy may be linked to an increased risk for cardiotoxicity in patients who survived cancer in childhood, according to a research letter published in the Journal of the American College of Cardiology.Using data from The University of Texas MD Anderson Cancer Center, Kara A. Thompson, MD, from the department of cardiology at the University of Texas, Houston, and colleagues evaluated the cardiac outcomes of childhood cancer survivors who were pregnant and who were previously exposed to anthracyclines and/or chest radiation.

      Read Full Article
    4. News digest – immunotherapy combo, ovarian drug disappointment, artificial DNA… and sunshine wristbands?

      News digest – immunotherapy combo, ovarian drug disappointment, artificial DNA… and sunshine wristbands?

      There were loads of stories this week from ASCO 2015, the world’s biggest cancer conference, in the US. You can read our detailed thoughts on the conference in this blog post – or read on for our media round-up, and – further down – the rest of the week’s news: The estimated cost in US Dollars for a course of the new combined immunotherapy treatment for melanoma (that’s over £131,000). Of course, there was plenty of other news this week too: More on this topic

      Read Full Article
      Mentions: ASCO
    5. Late mortality rates have declined in pediatric cancer survivors

      CHICAGO — The modification of therapy to reduce late treatment effects has led to a reduction in all-cause mortality over the past 3 decades among survivors of pediatric cancer, according to findings from the phase 3 Childhood Cancer Survivor Study presented at the plenary session of the ASCO Annual Meeting. Among 5-year survivors, all-cause mortality at 15 years from diagnosis declined from 12.4% for those treated between 1970 and 1974 to 6% for those treated between 1990 and 1994.

      Read Full Article
      Mentions: Treatment ASCO
    6. Immunotherapy Combo Increases Progression-free Survival in Advanced Melanoma Patients

      CHICAGO, IL, MAY 31, 2015 -- Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each patient's tumor has also given researchers clearer understanding of which patients should receive the combination. These initial findings from the phase III clinical ...

      Read Full Article
    7. SITC Reports on Immunotherapy Insights and Data Featured at ASCO...

      SITC Reports on Immunotherapy Insights and Data Featured at ASCO...

      SITC Reports on Immunotherapy Insights and Data Featured at ASCO Plenary Session Dr. Allison, Science of Oncology Award honoree, opens session with lecture The most heavily attended and popular session at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting – “The Plenary Session Including the Science of Oncology Award and Lecture” – prominently featured presentations by immunotherapy experts and members of the Society for Immunotherapy of Cancer (SITC).

      Read Full Article
      Mentions: Immunotherapy ASCO
    8. ASCO President Peter Yu, MD, on Big Data, Big Themes for Upcoming Annual Meeting

      In advance of the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), ASCO President Peter Yu, MD, spoke with Medscape and provided a brief primer on big data, one of the major themes of this year's meeting program. He also outlined the future of CancerLinQ™, ASCO's signature big data project.

      He also highlighted a number of important meeting themes for ASCO attendees and made the case about why oncologists are exactly the specialists to lead medicine in the development of big data.

      Read Full Article
    9. The UK Childhood Cancer Conference 2015

      The UK Childhood Cancer Conference 2015

      The UK Childhood Cancer Conference takes place on Friday 15th May this year, in association with Children’s Cancer and Leukaemia Group (CCLG) and Bethany’s Wish.  This fantastic event brings together paediatric oncology researchers, world-leading experts, allied health professionals working in the field of paediatric oncology, support groups, children’s cancer charities and most importantly parents of […]

      Read Full Article
    10. Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.

      Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.

      Ecancermedicalscience. 2014;8:463

      Authors: Bouche G, André N, Banavali S, Berthold F, Berruti A, Bocci G, Brandi G, Cavallaro U, Cinieri S, Colleoni M, Curigliano G, Desidero TD, Eniu A, Fazio N, Kerbel R, Hutchinson L, Ledzewicz U, Munzone E, Pasquier E, Graciela Scharovsky O, Shaked Y, Stěrba J, Villalba M, Bertolini F

      Read Full Article
    11. Research Round Up Podcasts: Brain Tumors and Childhood Cancers

      More research highlights from ASCO’s 2014 Annual Meeting with expert-led podcasts! Dr. Susan Chang, Director of Neuro-Oncology at University of California San Francisco, discusses the latest research highlights on brain and central nervous system tumors. She shares about how “there have been some impressive clinical results in solid tumors such as melanoma and renal cell tumor.

      Read Full Article
    12. Cost-effectiveness of metronomic approach to neuroblastoma and use alongside other therapies

      Cost-effectiveness of metronomic approach to neuroblastoma and use alongside other therapies

      Dr Sterba (University Children's Hospital Brno, Brno, Czech Republic) talks to ecancertv at the Metronomics in Chemotherapy Meeting in Milano about the benefits of metronomic therapy in treating neuroblastoma, including cost-effectiveness. In addition, he discusses the ways in which this approach can be combined with other treatment strategies such as immunotherapy.

      Read Full Article
      Mentions: Treatment
    13. Fenretinide (4-HPR)/Lym-X-Sorb (LXS) oral powder plus ketoconazole in patients with high-risk (HR) recurrent or resistant neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) Consortium trial.

      Background: Fenretinide (4-HPR), a cytotoxic retinoid with preclinical activity in neuroblastoma (NB), formulated as 4-HPR/LXS oral powder increased plasma levels over a capsule formulation but exhibited a PK plateau at higher doses (Pediatr Blood Cancer 60:1801, 2013). Two expansion cohorts were undertaken to assess effects on 4-HPR plasma levels of: 1) removing dietary restrictions, 2) adding ketoconazole, an inhibitor of 4-HPR metabolism.Methods: Eligible patients had high-risk NB with recurrent or refractory disease, including in complete response (CR) after relapse (Cohort One-only). 

      Read Full Article
    14. Emergence of new ALK mutations at relapse of neuroblastoma.

      Background: The ALK receptor tyrosine kinase is activated by point mutations in neuroblastoma and constitutes a potent therapeutic target in this disease. Methods: To evaluate the role of ALK mutations in neuroblastoma progression or relapse, we searched for ALK mutations in a large series of 54 paired diagnostic–relapse neuroblastoma samples using Sanger sequencing. When an ALK mutation was observed in one sample, deep sequencing was used to seek for a minor mutated component in the other sample. With a coverage of > 100,000, the background variability was 0.034% per base at each position, resulting in a sensitivity to ...

      Read Full Article
      Mentions: Relapse ALK
    15. Phase I/IIa multicenter trial for high-risk and recurrent neuroblastoma: Anti-GD2 antibody (ch14.18) immunotherapies using M-CSF or G-CSF.

      Category: Pediatric Oncology
      Session Type and Session Title: General Poster Session, Pediatric Oncology
      Abstract Number: TPS10095
      Citation: J Clin Oncol 32:5s, 2014 (suppl; abstr TPS10095)
      Author(s): 

      Hiroshi Kawamoto, Kenichi Yoshimura, Toshimi Kimura, Chika Nitani, Junichi Hara; National Cancer Center Hospital, Tokyo, Japan; Center for Clinical Research, Kobe University, Kobe, Japan; Tokyo Women's Medical University, Tokyo, Japan; Osaka City General Hospital, Osaka, Japan

      Read Full Article
    16. Phase I study of proteasome inhibitor bortezomib in combination with irinotecan in patients with relapsed/refractory neuroblatoma.

      Category: Pediatric Oncology
      Session Type and Session Title: General Poster Session, Pediatric Oncology
      Abstract Number: 10051
      Citation: J Clin Oncol 32:5s, 2014 (suppl; abstr 10051)
      Read Full Article
    17. Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: A report from the Children’s Oncology Group study ANBL0531.

      Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: A report from the Children’s Oncology Group study ANBL0531.

      Meeting: 2014 ASCO Annual Meeting
      Abstract No: 10006
      First Author: Clare Twist
      Category: Pediatric Oncology - Pediatric Solid Tumors

      Read Full Article
      Mentions: Treatment COG MYCN
    1-24 of 43 1 2 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles